Spinal matrix metalloproteinase 3 mediates inflammatory hyperalgesia via a tumor necrosis factor-dependent mechanism

Neuroscience

Volumn 200, Issue , 2012, Pages 199-210

  Christianson, C A ^a   Fitzsimmons, B L ^a   Shim, J H ^a,b   Agrawal, A ^a   Cohen, S M ^a   Hua, X Y ^a   Yaksh, T L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Hanyang University   (South Korea)

Author keywords

Allodynia; Hyperalgesia; Inflammation; Matrix metalloproteinase 3; Pain; Tumor necrosis factor

Indexed keywords

CELL MARKER; ETANERCEPT; GLIAL FIBRILLARY ACIDIC PROTEIN; IBA1 PROTEIN; ILOMASTAT; STROMELYSIN; STROMELYSIN INHIBITOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BEHAVIOR; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVE SITE; ENZYME INHIBITION; HYPERALGESIA; INFLAMMATION; INTRACELLULAR SIGNALING; LUMBAR SPINAL CORD; MICROGLIA; NERVE CELL CULTURE; NOCICEPTION; NONHUMAN; PERIPHERAL INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TACTILE STIMULATION; THERMAL HYPERALGESIA; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; DIPEPTIDES; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HYDROXAMIC ACIDS; HYPERALGESIA; IMMUNOGLOBULIN G; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MATRIX METALLOPROTEINASE 3; NEUROGLIA; PAIN MEASUREMENT; PAIN THRESHOLD; PHYSICAL STIMULATION; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, TUMOR NECROSIS FACTOR; SPINAL CORD; SULFONAMIDES; TIME FACTORS; TUMOR NECROSIS FACTORS;

EID: 84855188901     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.10.019     Document Type: Article

References (61)

1. Agnihotri R., Crawford H.C., Haro H., Matrisian L.M., Havrda M.C., Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 2001, 276:28261-28267.
2. Agrawal A., Romero-Perez D., Jacobsen J.A., Villarreal F.J., Cohen S.M. Zinc-binding groups modulate selective inhibition of MMPs. ChemMedChem 2008, 3:812-820.
3. Agrawal S.M., Lau L., Yong V.W. MMPs in the central nervous system: where the good guys go bad. Semin Cell Dev Biol 2008, 19:42-51.
4. Bertini I., Calderone V., Cosenza M., Fragai M., Lee Y.M., Luchinat C., Mangani S., Terni B., Turano P. Conformational variability of matrix metalloproteinases: beyond a single 3D structure. Proc Natl Acad Sci U S A 2005, 102:5334-5339.
5. Bertini I., Calderone V., Fragai M., Luchinat C., Mangani S., Terni B. Crystal structure of the catalytic domain of human matrix metalloproteinase 10. J Mol Biol 2004, 336:707-716.
6. Bunnett N.W. Protease-activated receptors: how proteases signal to cells to cause inflammation and pain. Semin Thromb Hemost 2006, 32(Suppl 1):39-48.
7. Cauwe B., Van den Steen P.E., Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 2007, 42:113-185.
8. Chakraborti S., Mandal M., Das S., Mandal A., Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003, 253:269-285.
9. Chao C.C., Hu S., Ehrlich L., Peterson P.K. Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-d-aspartate receptors. Brain Behav Immun 1995, 9:355-365.
10. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994, 53:55-63.
11. Choi J.I., Svensson C.I., Koehrn F.J., Bhuskute A., Sorkin L.S. Peripheral inflammation induces tumor necrosis factor dependent AMPA receptor trafficking and Akt phosphorylation in spinal cord in addition to pain behavior. Pain 2010, 149:243-253.
12. Clements J.M., Cossins J.A., Wells G.M., Corkill D.J., Helfrich K., Wood L.M., Pigott R., Stabler G., Ward G.A., Gearing A.J., Miller K.M. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol 1997, 74:85-94.
13. Czeschik J.C., Hagenacker T., Schäfers M., Büsselberg D. TNF-alpha differentially modulates ion channels of nociceptive neurons. Neurosci Lett 2008, 434:293-298.
14. Dirig D.M., Salami A., Rathbun M.L., Ozaki G.T., Yaksh T.L. Characterization of variables defining hindpaw withdrawal latency evoked by radiant thermal stimuli. J Neurosci Methods 1997, 76:183-191.
15. Duivenvoorden W.C., Hirte H.W., Singh G. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Invasion Metastasis 1997, 17:312-322.
16. Farooqui A.A., Horrocks L.A. Brain phospholipases A2: a perspective on the history. Prostaglandins Leukot Essent Fatty Acids 2004, 71:161-169.
17. Ganea E., Trifan M., Laslo A.C., Putina G., Cristescu C. Matrix metalloproteinases: useful and deleterious. Biochem Soc Trans 2007, 35:689-691.
18. Gawlak M., Górkiewicz T., Gorlewicz A., Konopacki F.A., Kaczmarek L., Wilczynski G.M. High resolution in situ zymography reveals matrix metalloproteinase activity at glutamatergic synapses. Neuroscience 2009, 158:167-176.
19. Gijbels K., Proost P., Masure S., Carton H., Billiau A., Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 1993, 36:432-440.
20. Grobelny D., Poncz L., Galardy R.E. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry 1992, 31:7152-7154.
21. Hua X.Y., Svensson C.I., Matsui T., Fitzsimmons B., Yaksh T.L., Webb M. Intrathecal minocycline attenuates peripheral inflammation-induced hyperalgesia by inhibiting p38 MAPK in spinal microglia. Eur J Neurosci 2005, 22:2431-2440.
22. Ito S., Kimura K., Haneda M., Ishida Y., Sawada M., Isobe K. Induction of matrix metalloproteinases (MMP3, MMP12 and MMP13) expression in the microglia by amyloid-beta stimulation via the PI3K/Akt pathway. Exp Gerontol 2007, 42:532-537.
23. Jacobsen F.E., Buczynski M.W., Dennis E.A., Cohen S.M. A macrophage cell model for selective metalloproteinase inhibitor design. Chembiochem 2008, 9:2087-2095.
24. Junger H., Sorkin L.S. Nociceptive and inflammatory effects of subcutaneous TNFalpha. Pain 2000, 85:145-151.
25. Kawasaki Y., Xu Z.Z., Wang X., Park J.Y., Zhuang Z.Y., Tan P.H., Gao Y.J., Roy K., Corfas G., Lo E.H., Ji R.R. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med 2008, 14:331-336.
26. Kim Y.S., Kim S.S., Cho J.J., Choi D.H., Hwang O., Shin D.H., Chun H.S., Beal M.F., Joh T.H. Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J Neurosci 2005, 25:3701-3711.
27. Knight C.G., Willenbrock F., Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett 1992, 296:263-266.
28. Kozai T., Yamanaka H., Dai Y., Obata K., Kobayashi K., Mashimo T., Noguchi K. Tissue type plasminogen activator induced in rat dorsal horn astrocytes contributes to mechanical hypersensitivity following dorsal root injury. Glia 2007, 55:595-603.
29. Lee R., Kermani P., Teng K.K., Hempstead B.L. Regulation of cell survival by secreted proneurotrophins. Science 2001, 294:1945-1948.
30. MacPherson L.J., Bayburt E.K., Capparelli M.P., Carroll B.J., Goldstein R., Justice M.R., Zhu L., Hu S., Melton R.A., Fryer L., Goldberg R.L., Doughty J.R., Spirito S., Blancuzzi V., Wilson D., O'Byrne E.M., Ganu V., Parker D.T. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem 1997, 40:2525-2532.
31. Malkmus S.A., Yaksh T.L. Intrathecal catheterization and drug delivery in the rat. Methods Mol Med 2004, 99:109-121.
32. Marchand F., Perretti M., McMahon S.B. Role of the immune system in chronic pain. Nat Rev Neurosci 2005, 6:521-532.
33. McMahon S.B., Cafferty W.B., Marchand F. Immune and glial cell factors as pain mediators and modulators. Exp Neurol 2005, 192:444-462.
34. Milligan E.D., Watkins L.R. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009, 10:23-36.
35. Mohan M.J., Seaton T., Mitchell J., Howe A., Blackburn K., Burkhart W., Moyer M., Patel I., Waitt G.M., Becherer J.D., Moss M.L., Milla M.E. The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry 2002, 41:9462-9469.
36. Noble L.J., Donovan F., Igarashi T., Goussev S., Werb Z. Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci 2002, 22:7526-7535.
37. Nuttall R.K., Silva C., Hader W., Bar-Or A., Patel K.D., Edwards D.R., Yong V.W. Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia. Glia 2007, 55:516-526.
38. Ogata Y., Enghild J.J., Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 1992, 267:3581-3584.
39. Pagenstecher A., Stalder A.K., Kincaid C.L., Shapiro S.D., Campbell I.L. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol 1998, 152:729-741.
40. Pontén F., Jirström K., Uhlen M. The human protein atlas-a tool for pathology. J Pathol 2008, 216:387-393.
41. Prast J., Saleh L., Husslein H., Sonderegger S., Helmer H., Knöfler M. Human chorionic gonadotropin stimulates trophoblast invasion through extracellularly regulated kinase and AKT signaling. Endocrinology 2008, 149:979-987.
42. Qiu Q., Yang M., Tsang B.K., Gruslin A. EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways. Reproduction 2004, 128:355-363.
43. Reeve A.J., Patel S., Fox A., Walker K., Urban L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. Eur J Pain 2000, 4:247-257.
44. Romero-Perez D., Agrawal A., Jacobsen J., Yan Y., Thomas R., Cohen S., Villarreal F. Effects of novel semiselective matrix metalloproteinase inhibitors on ex vivo cardiac structure-function. J Cardiovasc Pharmacol 2009, 53:452-461.
45. Rosenberg G.A., Navratil M., Barone F., Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 1996, 16:360-366.
46. Sawada M., Kondo N., Suzumura A., Marunouchi T. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res 1989, 491:394-397.
47. Schäfers M., Marziniak M., Sorkin L.S., Yaksh T.L., Sommer C. Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat. Exp Neurol 2004, 185:160-168.
48. Schönbeck U., Mach F., Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 1998, 161:3340-3346.
49. Shubayev V.I., Myers R.R. Upregulation and interaction of TNFalpha and gelatinases A and B in painful peripheral nerve injury. Brain Res 2000, 855:83-89.
50. Shubayev V.I., Myers R.R. Matrix metalloproteinase-9 promotes nerve growth factor-induced neurite elongation but not new sprout formation in vitro. J Neurosci Res 2004, 77:229-239.
51. Steenport M., Khan K.M., Du B., Barnhard S.E., Dannenberg A.J., Falcone D.J. Matrix metalloproteinase (MMP)-1 and MMP-3 induce macrophage MMP-9: evidence for the role of TNF-alpha and cyclooxygenase-2. J Immunol 2009, 183:8119-8127.
52. Stellwagen D., Beattie E.C., Seo J.Y., Malenka R.C. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 2005, 25:3219-3228.
53. Svensson C.I., Marsala M., Westerlund A., Calcutt N.A., Campana W.M., Freshwater J.D., Catalano R., Feng Y., Protter A.A., Scott B., Yaksh T.L. Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing. J Neurochem 2003, 86:1534-1544.
54. Svensson C.I., Schäfers M., Jones T.L., Powell H., Sorkin L.S. Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38. Neurosci Lett 2005, 379:209-213.
55. Tsuda M., Inoue K., Salter M.W. Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia. Trends Neurosci 2005, 28:101-107.
56. Vergnolle N., Bunnett N.W., Sharkey K.A., Brussee V., Compton S.J., Grady E.F., Cirino G., Gerard N., Basbaum A.I., Andrade-Gordon P., Hollenberg M.D., Wallace J.L. Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nat Med 2001, 7:821-826.
57. Vidal A., Sabatini M., Rolland-Valognes G., Renard P., Madelmont J.C., Mounetou E. Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases. Bioorg Med Chem 2007, 15:2368-2374.
58. Watkins L.R., Maier S.F. Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2003, 2:973-985.
59. Yong V.W., Power C., Forsyth P., Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001, 2:502-511.
60. Youn D.H., Wang H., Jeong S.J. Exogenous tumor necrosis factor-alpha rapidly alters synaptic and sensory transmission in the adult rat spinal cord dorsal horn. J Neurosci Res 2008, 86:2867-2875.
61. Zhang H., Nei H., Dougherty P.M. A p38 mitogen-activated protein kinase-dependent mechanism of disinhibition in spinal synaptic transmission induced by tumor necrosis factor-alpha. J Neurosci 2010, 30:12844-12855.